Top 50 Health Care Startup Investors in Switzerland in October 2023
Top 50 Health Care Startup Investors in Switzerland in October 2023
Get 300+ niche investors in 2 minutes.
Find who invests in your industry, stage, and region in our 200k+ database with AI-powered matching.
Find investors — It's Free!Trusted by 21,000+ founders from:
Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.
Show more...Investment focus
- Health Care, Medical Device, Biotechnology
- Seed, Series A, Funding Round
- Switzerland, Japan, Germany
Portfolio highlights
- Helio — Carbon Aware Cloud Computing.
- Tune Insight — Tune Insight orchestrates secure collaborations on sensitive data between multiple organizations to extract collective insights.
- Nagi Bioscience — Enabling small organisms testing to any lab. Unleash unique datapoints efficiently at a high-throughput rate.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Health Care, Software, Biotechnology
- Series A, Seed, Series B
- Switzerland, Germany, France
Portfolio highlights
- MedTrace Pharma — MedTrace develops a hardware platform (MT-100) that automates the production and injection of the gold standard tracer 15O-water into the patient. MedTrace also develops an analytical software platform to interpret the results from the PET scanner.By use of 15O-water, doctors will increase sensitivity in the analysis of the patient while at thesame time increasing patient throughput up to a factor of 4 compared to today's clinical workhorse.
- Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
- Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
The Foundation for Technological Innovation (FIT) has been helping startups since 1994, encourages entrepreneurship & supports innovation.
Show more...Investment focus
- Health Care, Biotechnology, Information Technology
- Debt Financing, Grant, Seed
- Switzerland, France
Portfolio highlights
- Voltiris — Voltiris filters natural sunlight to transmit it to plants and recycle the "wasted" sunlight into green electricity.
- PeriVision — Perivision combines artificial intelligence, virtual reality, and the cloud to build the next generation of systems to understand visual function. The company's systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
- AdVentura Works — AdVentura Works is a Swiss technology company offering material handing as a service to logistics and industrial companies
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Switzerland, Germany, France
Portfolio highlights
- Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.
Show more...Investment focus
- Health Care, Biotechnology, Medical Device
- Series A, Series C, Series B
- Switzerland, Germany, United States
Portfolio highlights
- Vara — Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with.
- Oculis — The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
- Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
Redalpine is one of the leading European Venture Capital investors with a focus on highly scalable start-ups. The firm's mission is to help talented entrepreneurs turn an ambitious vision into reality by providing money, experience, coaching, and a strong network. The firm is focused on seed and early-stage investments in disruptivetechnologies in tech and health tech. Redalpine launched its first fund (Redalpine Capital I) in 2007, following the founding partners’ track record of some excellent trade sales and IPOs as serial entrepreneurs and professional angel investors. In 2021 Redalpine closed its sixth fund (Redalpine Capital VI) and currently has approx. USD 1 Billion in AUM. The highly interdisciplinary Redalpine team supports more than 70 portfolio companies with operational and sector-specific expertise and with a rich international network.Redalpine started with its first fund (Redalpine Capital I) in 2007 based on the track-record of some excellent trade-sales and IPOs as serial entrepreneurs and professional angel investors. Redalpine sucessfully launched Redalpine Capital II in 2012 and Redalpine Capital III in 2016. The funds are registered in Luxemburg and backed by dozens of experienced entrepreneurs and investors representing various countries, and a broad range of industries.
Show more...Investment focus
- Software, Biotechnology, Health Care
- Series A, Seed, Series B
- Germany, Switzerland, United Kingdom
Portfolio highlights
- Zealy — A simple, fun & creative way to join trendy communities, make an impact and earn rewards.
- Genialis — Genialis is a precision medicine data science company focused on new ways to treat disease. Blending computational biology and AI-based methods, Genialis merges and models data at the intersection of clinical and translational medicine and drug discovery. Genialis is trusted by biopharma and big pharma alike, to validate targets, predict biomarkersand optimally position novel drugs. Together, Genialis and its partners are bringing improved solutions to drug discovery to change people's lives.
- Umiami — Umiami Technologies is a leader in plant-based meat. Our proprietary technology allows us to create clean-label and incredibly tasty foods.
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more...Investment focus
- Biotechnology, Pharmaceutical, Health Care
- Seed, Series C, Funding Round
- Switzerland
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Switzerland, United Kingdom
Portfolio highlights
- CellFE — CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.
- BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
- Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.
Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.
Show more...Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- Switzerland, United States, India
Portfolio highlights
- Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399, all this while you sit in the comfort of your home. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able todo in India yet.The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery.Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision are to name a few) and be it disposable, toric, colored or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.
Show more...Investment focus
- Software, Health Care, Information Technology
- Seed, Angel, Series A
- Switzerland, Spain, Austria
Portfolio highlights
- Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
- GUURU — Convert undecided shoppers into confident buyers with instant, authentic advice from your expert community.
- Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.
Bernina BioInvest is an investment Firm.
Show more...Investment focus
- Biotechnology, Health Care, Biopharma
- Seed, Series A, Series B
- Switzerland
Portfolio highlights
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
How to Invest in Swiss Startups That Last The Investor community of the Swiss ICT Investor Club (SICTIC) helped to fund to more than 160 Swiss tech startups to date. While doing so, they learned a lot about what to watch out for and how to foster success. Read more Get your FREE angel handbook
Show more...Investment focus
- Software, Information Technology, Artificial Intelligence
- Seed, Pre-Seed, Series A
- Switzerland, Germany, United Kingdom
Portfolio highlights
- Axom — Axom automating visual inspection through image analysis in the healthcare industry.
- Gaia Tech — Gaia Technologies turns agricultural sidestreams into high-value ingredients for cosmetics, food, and feed manufacturers.
- PeriVision — Perivision combines artificial intelligence, virtual reality, and the cloud to build the next generation of systems to understand visual function. The company's systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
StartAngels Network is a Zurich-based angel investment firm that provides investment consulting services.
Show more...Investment focus
- Medical Device, Health Care, Medical
- Seed, Series A, Series B
- Switzerland, Brazil
Portfolio highlights
- Medyria — Medyria is a Swiss medtech startup that engineers technologies for cardiovascular catheter navigation and sensing. They develop a unique guiding and sensing medical device based on proprietary Blood Flow Velocity Sensor technology. The TrackCath System is designed to be cost-effective and safe during EVAR procedures.Medyria's goal is todevelop devices that enable safer and more effective endovascular procedures. It was founded in 2014 and is based in Winterthur, Zurich, Switzerland.
- Pipra — PIPRA AG (Pre-Interventional Preventive Risk assessment) is developing a cutting-edge AI-based pre-operative test to assess a patient's risk of suffering from cognitive disorders after surgery.
- Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Information Technology, Medical, Software
- Funding Round, Seed, Series A
- Switzerland, Germany, United Kingdom
Portfolio highlights
- LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
- AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
- Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 500 startups since 2005. Driven by their expertise, entrepreneurial spirit, and passion, its teamof experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry, and life sciences.To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.
Show more...Investment focus
- Software, Information Technology, Biotechnology
- Seed, Series A, Funding Round
- Germany, Switzerland, United States
Portfolio highlights
- Inovedis — Inovedis offers innovative solutions in medical technology that contribute both to optimized patient care as well as time and cost reductions in the healthcare sector.
- Resourcify — Mein Recycling is developed by Resourcify GmbH from Hamburg. The app is the easiest solution for businesses to easily manage all of their waste, collections, and recyclers in one app, and for waste management companies to seamlessly connect with their customers online. Their vision is zero-waste: enabled with the digital transformation of the wastesector as the foundation for the circular economy.
- traceless materials — traceless materials offer a holistically sustainable alternative to plastics: 100% biobased on plant residues, compostable under natural conditions, and free of toxic chemicals. For a future free of pollution and waste!
Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world
Show more...Investment focus
- Financial Services, FinTech, Software
- Seed, Series A, Funding Round
- Switzerland, United States, Spain
Portfolio highlights
- yamo — Frische Bio-Kindernahrung von yamo, so lecker wie selbstgemacht und kostenlos direkt zu dir nach Hause geliefert. Jetzt probieren und profitieren.
- Relai — Relai is a Bitcoin investment app that allows anyone to buy bitcoin within one minutes or set up an automated savings plan.
- Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
Alpana Ventures is a Swiss VC focusing on digital transformation.Since 2016 we backed 45 founder teams with 3 Funds, supporting them in their journey towards a positive impact.Committed to value creation, we discover deep tech solutions in Switzerland, Europe and the US.We invest to embed them into innovative business models and back them tobecome global market leaders.Applying ESG criteria, our portfolio companies help create a more sustainable future.
Show more...Investment focus
- Software, FinTech, Information Technology
- Seed, Series A, Series B
- United States, Switzerland, Germany
Portfolio highlights
- Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
- Nezasa — Nezasa’s travel booking solution empowers travel brands globally to combine all planning and booking related actions into one seamless end-to-end experience.Our tools, enable to plan and book any type of multi-product or multi-stop itinerary.TripBuilder Hyper-personalised packaging Real-time planning and booking of personalised itinerariesPowerful, easy to use and very interactive Deep integration possibilities into existing fulfilment landscapes Enterprise-grade, proven with large TO customersTripBooster Hyper-personalised In-Destination Upselling The extension of TripBuilder’s power throughout the entire travel lifecycle The perfect travel companion Seamless purchasing of perfectly fitting additional products Smart upselling recommendation, available in both a push and pull mode
- Tinamu — Tinamu Labs has developed a technology that converts commercially available drones into camera equipment reaching professional standards.
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more...Investment focus
- Health Care, Biotechnology, Software
- Funding Round, Series A, Seed
- United Kingdom, United States, Switzerland
Portfolio highlights
- Cobee — Cobee develops an online platform that automates and simplifies employee benefits management. The company also provides benefits for employees and flexible compensation that makes companies and employees fall in love. It facilitates the management of your benefits plan and allows you to focus on what really matters.Cobee provides a subsidy toyour employees to complement the cost of the benefits you want. They eliminate intermediaries and external suppliers of each of the benefits, thus achieving such as reduce costs and improve service quality for companies and employees, create a single source of information, which facilitates the management, resolution of incidents and the visibility of what happens in each moment, and offer your employees a benefits package centralized on the same VISA card, with real-time visibility of the savings generated and controlled from their Cobee App.Cobee was founded in 2018 and is headquartered in Madrid, Spain.
- Nanoflex Robotics — Nanoflex Robotics develops a soft robotic system that precisely inserts specially made guidewires and catheters deep into the brain. The company provides patented magnetic navigation technology but also the necessary surgical devices. Nanoflex Robotics was established in May, 2021 in Zurich, Switzerland.
- PreComb Therapeutics — functional precision medicine, oncology, cancer, discovery, organoid, predictive, ai, 3DTwin, data mining, therapy guidance, automated, immune oncology, 2curex, xilis, usz, dkfz, nct, switzerland
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more...Investment focus
- Health Care, Medical, Biotechnology
- Seed, Series A, Series B
- Switzerland
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.
Btov Partners is a venture capital firm focused on early-stage investments in digital and industrial technology companies. With investment teams in Digital and Industrial Tech, Btov invests EUR 50m per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.
Show more...Investment focus
- Software, Health Care, Information Technology
- Series A, Seed, Series B
- Germany, Switzerland, United Kingdom
Portfolio highlights
- AI21 Labs — AI21 Labs is an AI lab & product company whose mission is to reimagine the way we read and write by making the machine a thought partner to humans.
- Calvin Risk — We help companies manage the risks of their AI algorithms!
- NVision Imaging Technologies — NVision Imaging Technologies is leveraging advances in quantum physics to enable the first routine, convenient and affordable use of Magnetic Resonance Imaging (MRI) for assessing early patient response to cancer treatment at the metabolic level.
4FO Ventures
Show more...Investment focus
- Artificial Intelligence, Health Care, Medical
- Series A, Seed, Series B
- Switzerland
Portfolio highlights
- ecoRobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
- ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.
- Giotto.ai — We complement modern machine learning with topology, the science of shapes. Increased interpretability and robustness are the direct benefits of this novel approach.Our first product, Giotto Compliance (compliance.giotto.ai), facilitates the consolidation of clinical evidence in the context of regulatory processes by leveraging proprietary NLPtechnology. This state-of-the-art AI software allows significant time and cost savings for medical device companies and medical writers.
EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Show more...Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, The Netherlands, Switzerland
Portfolio highlights
- VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
- Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.
Show more...Investment focus
- Software, SaaS, Information Technology
- Funding Round, Series B, Series A
- Switzerland, United States, France
Portfolio highlights
- viboo — viboo offers self-learning predictive control on the basis of physics-informed Machine Learning as a cloud service to smart-thermostat and building automation companies.
- ecoRobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
- AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
We dedicate our know-how, experience and energy to the new generation of startup founders, helping them navigate the skies on their way to success.
Show more...Investment focus
- Software, Artificial Intelligence, SaaS
- Pre-Seed, Seed, Series A
- Switzerland, United Kingdom
Portfolio highlights
- Ascento — Secure, maintain, and inspect outdoor assets by reducing the intervention times and augmenting data capturing capability.
- Tune Insight — Tune Insight orchestrates secure collaborations on sensitive data between multiple organizations to extract collective insights.
- Saeki Robotics — Building the future of autonomous robotic manufacturing.
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program.We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. SectorsNew therapeutics & platformsMedical devices/implantsDiagnostics/biomarkersDrug delivery/biopolymersGeographyUSA/CanadaEuropeSwitzerlandAsia/Pacific
Show more...Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
- Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
- Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.
Show more...Investment focus
- Health Care, Medical Device, Biotechnology
- Series A, Seed, Series B
- Switzerland, Sweden, United States
Portfolio highlights
- Evismo — Evismo provides diagnostics services in Switzerland
- Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
- Flow Neuroscience — Flow Neuroscience is a healthcare company that develops depression treatment devices that combines an easy-to-use brain stimulation headset with a personalized mobile app to target both the physical and behavioral elements of Major Depressive Disorder (MDD). The company's wearable stimulates a patient's left frontal lobe, the area of thebrain that has often lowered activity in people suffering from depression.Flow Neuroscience combines their wearable with a mobile app that nudges users to behaviors that will help lessen the effects of their depression, including exercise and regular sleeping patterns.The company's hope is to make available for the public a treatment that's currently only used in clinics specialized in brain stimulation. It also wants to make the treatment affordable enough to seriously challenge a dominant pharmaceuticals industry.
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
Show more...Investment focus
- Health Care, Medical, Personal Health
- Series A, Seed, Series B
- Switzerland, India, France
Portfolio highlights
- Ava — Ava makes it easy to gain a profound and accurate understanding of your cycle and health—empowering you to make informed choices for your life. Because we believe every woman deserves greater control over her wellbeing, and the tools to maximize her physical and emotional potential.
- CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
- 99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Denmark, United Kingdom
Portfolio highlights
- Octave — Octave is a national behavioral health practice that’s creating a new standard for care delivery that’s both high-quality and accessible to more people. With in-person and virtual clinics in California and New York, the company offers personalized care plans that can include individual therapy, couples therapy, and groups, while pioneeringrelationships with payers to make care more affordable through insurance. Grounded in science, Octave enables clients to experience profound change that is as measurable as it is meaningful.
- Acesion Pharma — Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
- Alentis Therapeutics — Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- France, United States, United Kingdom
Portfolio highlights
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
- Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
- Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.
Occident macht Investments in Deep Tech Startups aus den Bereichen Lifesciences, Hightech und Digital. Finanzierung ab Seed-Finanzierungsrunde
Show more...Investment focus
- Health Care, Medical Device, Biotechnology
- Series A, Series C, Funding Round
- Germany, Switzerland
Portfolio highlights
- ReCatalyst — REvolutionizing the way we make fuel cell CATALYSTs
- iThera Medical — Due to its spatiotemporal resolution, penetration depth, sensitivity and specificity, optoacoustic imaging (OAI) can be used for a multitude of applications.
- Lunaphore — Lunaphore Technologies is a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Switzerland, Canada
Portfolio highlights
- Kate Therapeutics — Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases.
- Nexo Therapeutics — Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
- Tentarix Biotherapeutics — Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.
Venture capital for companies developing innovative therapeutics.
Show more...Investment focus
- Biotechnology, Therapeutics, Health Care
- Series A, Series B, Series C
- Switzerland, France, The Netherlands
Portfolio highlights
- Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
- Alentis Therapeutics — Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.
- Ariceum Therapeutics — Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Ralph Gygax is a Chief Administrative Officer at SWISS Gate AG. He attended KV, SVIT from 1999 to 2007.
Show more...Investment focus
- Cannabis, Wellness, Cosmetics
- Seed, Pre-Seed, Series A
- Switzerland
Portfolio highlights
- SWISS Gate AG — SWISS Gate AG is a family-run Swiss company founded in November 2019 by brothers Dominic, Marco & Michael Hoffmann with the support of their father Werner Hoffmann and uncle Ralph Gygax.SWISS Gate AG focuses with its positioning on the areas of Lifestyle & Wellbeing. The offered product assortment ranges from CBD Anti-Aging and Day Creamsto Skin Creams as well as Shampoo, Shower Gel or Conditioner to Hemp Foods like Hemp Tea or Hemp Seed Oils to CBD Hemp Flowers to CBD Hemp Oil for humans and animals.SWISS Gate AG exclusively distributes its products of the company-owned brands Herbalea and Old Donald's through selected resellers as well as through the company-owned e-commerce channel cbuy.ch - Alles Gute aus Cannabis.SWISS Gate AG manufactures all products together with exclusive partners from the cosmetics, food & consumer goods industry and has the exclusive production & distribution rights over the products.SWISS Gate AG has launched its Series A financing round in mid-September 2021 with the goal to raise CHF 5'000'000. Currently, CHF 200,000 of this amount has been raised. The financing round is currently open - interested parties can contact CEO Marco Hoffmann directly via the contact details.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Biotechnology, Health Care, Medical
- Funding Round, Series B, Series A
- Denmark, Sweden, Switzerland
Portfolio highlights
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Good Seed Ventures is a Venture Capital firm that exclusively invests in sustainable food tech.
Show more...Investment focus
- Food and Beverage, Food Processing, Biotechnology
- Seed, Series A, Pre-Seed
- Germany, Israel, United States
Portfolio highlights
- Perfeggt — We harness the power of plants and cutting-edge technology to crack the egg.
- Libre Foods — Libre Foods is a biotech startup on a mission to liberate the food system and create a more free future for people, the planet, and animals. The company was founded in 2020 and is based in Barcelona, Catalonia, Spain.
- Nosh Biofoods — Nosh Biofoods is a developer of traditional meat.It produces technical-functional components and nutritional protein by utilising manufacturing technologies to explore natural microbial biodiversity.
Joyance Partners is the first venture fund supporting companies that deliver Delightful Moments derived from science - a new, transformative cycle of human experience that we see as one of the greatest investment opportunities in decades.
Show more...Investment focus
- Health Care, Biotechnology, Wellness
- Seed, Series A, Funding Round
- United States, Germany, Switzerland
Portfolio highlights
- Mosh — MOSH is a mission-focused, family-run company to get you thinking more about your brain health! Try our MOSH bars formulated with superfoods & vital brain nutrients.
- Scent Lab — A hyper-personalized approach to fragrance. We leverage data & science in our Scent Discovery Quiz to curate your perfect scent and personalized candle.
- Alba Health — Discover your baby's gut health & microbiome for the best start in life.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Health Care, Artificial Intelligence, Medical
- Seed, Pre-Seed, Series A
- United States, United Kingdom, Austria
Portfolio highlights
- basys.ai — Basys.ai automates the process of prior authorization and utilization management to improve costs and timeliness for health plans/payers using an AI-based platform. The proprietary platform automates the process of encoding/digitizing the payer policies using machine learning, thus reducing the piloting timeline by up to 9 months.
- Lillian Care — Lillian is building a nationwide network of health facilities in Germany.
- ALFIE — AI software platform that provides consistent and automated measurements from radiographic images used to assess spinal disorders.
Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.
Show more...Investment focus
- Software, E-Commerce, Internet
- Series A, Series B, Seed
- United States, United Kingdom, France
Portfolio highlights
- Apron — Sort, pay and reconcile your invoices in seconds.
- Worldover — Cosmetic compliance made simple
- Class Companion — Class Companion is a new AI technology that allows professors to provide students with immediate, individualized feedback.
Privilege Ventures is the venture capital arm of Privilège Management and invest in seed and early stage companies. Geographical focus is Switzerland and the rest of Europe. Focus sectors are industrial-tech, med-tech, wearables and in general ICT.
Show more...Investment focus
- Health Care, Hardware, Software
- Seed, Series A, Funding Round
- Switzerland, France
Portfolio highlights
- Wyth — Wyth makes technologies that help humans create meaningful relationships by bringing emotions, stories and connections beyond the interface.
- Smeetz — Smeetz is the future of a unified, data-driven and dynamic pricing-oriented commerce for attractions and cultural venues.
- Avelo — Our mission is to save lives by bringing fast and actionable infectious disease diagnosis closer to the patient. Avelo's solution is a breath collection device. It works with existing molecular tests to detect multiple respiratory tract infections causing pneumonia
Professional experience: Expert for Risk Management and Public Relations Strategic & operational responsibility Compliance & Safety Management Decades of leadership experience as colonel & professional military pilot in the Swiss Air Force
Show more...Investment focus
- Cannabis, Wellness, Cosmetics
- Seed, Series A
- Switzerland
Portfolio highlights
- SWISS Gate AG — SWISS Gate AG is a family-run Swiss company founded in November 2019 by brothers Dominic, Marco & Michael Hoffmann with the support of their father Werner Hoffmann and uncle Ralph Gygax.SWISS Gate AG focuses with its positioning on the areas of Lifestyle & Wellbeing. The offered product assortment ranges from CBD Anti-Aging and Day Creamsto Skin Creams as well as Shampoo, Shower Gel or Conditioner to Hemp Foods like Hemp Tea or Hemp Seed Oils to CBD Hemp Flowers to CBD Hemp Oil for humans and animals.SWISS Gate AG exclusively distributes its products of the company-owned brands Herbalea and Old Donald's through selected resellers as well as through the company-owned e-commerce channel cbuy.ch - Alles Gute aus Cannabis.SWISS Gate AG manufactures all products together with exclusive partners from the cosmetics, food & consumer goods industry and has the exclusive production & distribution rights over the products.SWISS Gate AG has launched its Series A financing round in mid-September 2021 with the goal to raise CHF 5'000'000. Currently, CHF 200,000 of this amount has been raised. The financing round is currently open - interested parties can contact CEO Marco Hoffmann directly via the contact details.
Donations enable exceptional things to happen and contribute to solutions for the great challenges of our time.
Show more...Investment focus
- Information Technology, Medical Device, Health Care
- Seed, Grant, Series A
- Switzerland
Portfolio highlights
- Auxivo — We are Auxivo, an exoskeleton company committed to improving people's lives through innovative and accessible exoskeletons.
- Adresta — Adresta is a tech start-up with six employees headquartered in Zurich and founded in December 2019. The idea started with two co-founders in the Kickbox Programm of Helvetia Insurance and the product was developed together with the third co-founder at ETH Zurich. Adresta creates digital certificates for luxury goods, starting with high-endtimepieces. The certificates are securely stored on the web-application together with the history of the watch from manufacturer to service & repair and pre-owned sale. Around the constantly updated digital certificate new possibilities of customer experience in the luxury segment arise. Brands create emotions and interaction possibilities for the actors in the watch lifecycle and after sales processes such as valuable insurance are facilitated. Adresta is committed to change the customer experience in the luxury goods industry by creating trust and transparency by combining new technologies.
- Planted Foods — Planted is an ETH Spinoff that uses cutting-edge technology to turn four natural ingredients into plant-based meat that mimics the taste, texture, and mouthfeel of traditional animal meat. It takes only the best raw materials from plants and creates that tasty, nutritious, high-protein, and juicy planted that the customers love.It was founded in2019 and is headquartered in Zürich, Switzerland.
New Enterprise Associates, Inc. is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’slifecycle, from the seed stage through IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.
Show more...Investment focus
- Software, Health Care, Biotechnology
- Series B, Series A, Series C
- United States, India, China
Portfolio highlights
- Meeno — Meeno is a relationship mentoring app powered by generative AI
- Rocket.Chat — Explore Rocket.Chat, where we put data privacy into every conversation and enable teams to collaborate seamlessly.
- Pulumi — Pulumi's open source infrastructure as code SDK enables you to create, deploy, and manage infrastructure on any cloud, using your favorite languages.
Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.
Show more...Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- Switzerland, United States, Denmark
Portfolio highlights
- Bird Rock Bio — We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.
- Synaffix BV — Synaffix BV is a clinical-stage, Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) thatenables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035.Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products for their own pipelines.Disclosed partnerships to date include those with ADC Therapeutics and Mersana Therapeutics
- Bellerophon Therapeutics — Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitricoxide delivery device, INOpulse®, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of PH-COPD. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack).
Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.
Show more...Investment focus
- Health Care, Biotechnology, Medical Device
- Grant, Pre-Seed, Seed
- Switzerland, United States, Taiwan
Portfolio highlights
- Pelt8 — Pelt8 enables climate action through the platform with scalable processes and controls to collect sustainability-related data in an easy and traceable way.
- Atinary — Atinary is an end-to-end AI, machine learning, robotics, and cloud computing technology platform for digitizing R&D operations.
- Ascento — Secure, maintain, and inspect outdoor assets by reducing the intervention times and augmenting data capturing capability.
Endeavour Vision is a venture capital and growth equity firm investing in transformative healthcare technologies.
Show more...Investment focus
- Health Care, Medical, Biotechnology
- Series C, Series B, Series A
- United States, Switzerland, France
Portfolio highlights
- Venture Med Group — VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients.Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly costeffective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.
- Miach Orthopaedics — Miach Orthopaedics is a medical device company that develops bio-engineered surgical implants to facilitate new tissue growth. The company's product is the Bridge-Enhanced ACL Repair technology as a viable alternative to conventional ACL reconstruction for patients who have withstand an anterior cruciate ligament injury.Miach Orthopaedicswas founded on 2016 and is headquartered in Westborough, Massachusetts.
- Relievant Medsystems — Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain.
Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more...Investment focus
- Medical, Health Care, Biotechnology
- Seed, Series A
- Switzerland
Portfolio highlights
- Microcaps — Microcaps provides a novel solution to encapsulate ingredients naturally, protect them an enhance them with high-end appearence
- Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
- MUVON Therapeutics — Muvon Therapeutics platform helps women with urinary incontinence and treats diseases based on skeletal muscle degradation, supporting them in their commitment to living a healthy life. The company's mode of contact is by mail, phone, and physical address.
Patrick Lütjens is an investor, an Experienced Senior Consultant with a demonstrated history of working in the venture capital and private equity industry.
Show more...Investment focus
- iOS, SaaS, Mobile
- Seed, Angel, Series A
- Switzerland
Portfolio highlights
- Uepaa® — Uepaa AG is the Lone Worker Safety and Peer2Peer (P2P) communication pioneer for mobile devices. After 10+ years of research, Uepaa AG has developed a revolutionary wireless P2P communication technology. Its first product - the Uepaa! Safety app - launched in 2013, successfully showcased this technology’s leadership position. This award-winningproduct evolved into today's industry standard for mobile-based lone worker safety protection. The daily companion for thousands of employees and field forces - working at risk or alone. Uepaa AG, founded in January 2012 by Mathias Haussmann and Dr Franck Legendre, is a Swiss ETH spin-off, headquartered in Zürich.
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated teamof investment advisors and an advisory board. In addition, it is supported by all of the Group’s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.
Show more...Investment focus
- Biotechnology, Health Care, Medical
- Series C, Series A, Funding Round
- United States, Switzerland, Italy
Portfolio highlights
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- Moderna — Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies insidepatient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.
- Aleva Neurotherapeutics — Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.
NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.
Show more...Investment focus
- Health Care, Biotechnology, Medical
- Series B, Series C, Funding Round
- Switzerland, United States, Italy
Portfolio highlights
- Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
- Oxular — Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
- JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.
Show more...Investment focus
- Health Care, Medical Device, Medical
- Grant, Pre-Seed, Seed
- United Kingdom, Spain, Ireland
Portfolio highlights
- Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
- ZiO Health — ZiO Health develops multi-functional electronic devices for measuring, testing and detecting the molecular composition of chemical and biological substances for the presence, absence, or quantity of target molecules.
- Nanordica Medical — Nanordica Medical develops novel nanoparticle-based antibacterial wound care products.
Close your round
Find who invests in your industry, stage, and region in our 200k+ database with AI-powered matching.
Find investors — It's Free!Join 21,000+ founders from: